GRM3 and psychotic disorder: MP-101 is a novel metabotropic glutamate receptor type 2 (mGluR2) and 3 (mGluR3) agonist currently being evaluated in a phase II trial (NCT03044249) for the treatment of dementia-related psychosis, with results expected in 2021 (https://clinicaltrials.gov/ct2/show/NCT03044249).